Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Donald Arents

Pulmonary Disease Venice, FL Medical Doctor

NPI 1770655532 CMS profile 261713

219 Palermo Pl, Venice, FL 34285

Open in the dashboard

General payments

$194,013

225 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Donald Arents of Venice, FL is reported in the CMS Open Payments database as having received $194,013 across 225 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $10,639 9
2021 General $20,275 42
2020 General $51,227 57
2019 General $111,872 117

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donald Arents
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Donald Arents were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Donald Arents Pulmonary Disease median Middle half National median
2019 $111,872 $377 $109–$1,340 $163
2020 $51,227 $230 $56–$907 $114
2021 $20,275 $269 $68–$1,072 $132
2022 $10,639 $390 $100–$1,457 $149
2023 $0 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. GlaxoSmithKline, LLC. $177,759 163 payments
  2. Mylan Specialty L.P. $15,590 38 payments
  3. AstraZeneca Pharmaceuticals LP $362 10 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $109 4 payments
  5. Regeneron Healthcare Solutions, Inc. $65 3 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $33 2 payments
  7. Sunovion Pharmaceuticals Inc. $23 1 payment
  8. Novartis Pharmaceuticals Corporation $23 1 payment
  9. Merck Sharp & Dohme Corporation $21 1 payment
  10. Gilead Sciences, Inc. $14 1 payment
  11. Other $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $184,638 76 payments
  2. Food and Beverage $5,265 127 payments
  3. Travel and Lodging $3,860 21 payments
  4. Consulting Fee $250 1 payment
Products named General payments · program years 2019–2022
  1. TRELEGY ELLIPTA $150,846 111 payments
  2. Yupelri Respiratory and Allergy $15,503 37 payments
  3. NUCALA Respiratory $10,355 19 payments
  4. ANORO $8,418 9 payments
  5. ANORO ELLIPTA $7,909 16 payments
  6. BREZTRI $261 4 payments
  7. NUCALA Immunology $252 10 payments
  8. SPIRIVA RESPIMAT $109 4 payments
  9. YUPELRI Anticholinergics, Inhaled $87 1 payment
  10. DUPIXENT $65 3 payments
  11. Other $403 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

225 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record